Cowen analyst Yaron Werber raised the firm’s price target on BeiGene to $262 from $213 and keeps an Outperform rating on the shares. The analyst said Q4 product revenues were hit by COVID in China but we remain optimistic about Brukinsa given its best-in-class profile and US approval in CLL.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BGNE: